Discontinued — last reported Q2 '22
BioPharma Systems — Revenue
Becton, Dickinson and Company BioPharma Systems — Revenue decreased by 87.5% to $590.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 86.8%, from $4.48B to $590.00M. Over 4 years (FY 2021 to FY 2026), BioPharma Systems — Revenue shows a downward trend with a -13.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong demand for drug delivery solutions and successful partnerships with pharmaceutical companies.
Detailed definition
This metric represents the total gross sales generated by the BioPharma Systems business unit, which provides drug deliv...
Peer comparison
Similar to revenue reporting for specialized medical device or drug delivery components at peer life science companies.
bdx_segment_biopharma_systems_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.61B | $4.30B | $4.72B | $4.75B | $4.64B | $4.76B | $4.59B | $4.82B | $4.88B | $5.09B | $4.71B | $5.05B | $4.99B | $5.44B | $5.17B | $418.00M | $4.48B | $575.00M | $5.51B | $6.68B | $5.25B | $429.00M | $4.71B | $590.00M |
| QoQ Change | — | -6.6% | +9.7% | +0.7% | -2.3% | +2.6% | -3.7% | +5.1% | +1.2% | +4.3% | -7.5% | +7.2% | -1.1% | +9.0% | -4.9% | -91.9% | +971.8% | -87.2% | +858.1% | +21.3% | -21.4% | -91.8% | +998.8% | -87.5% |
| YoY Change | — | — | — | — | +0.7% | +10.7% | -2.8% | +1.5% | +5.1% | +6.8% | +2.6% | +4.6% | +2.3% | +6.9% | +9.8% | -91.1% | -11.2% | -88.6% | +10.4% | +22.9% | +1.6% | -91.7% | +5.2% | -86.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — revenue?
- Becton, Dickinson and Company (BDX) reported biopharma systems — revenue of $590.00M in Q1 2026.
- How has Becton, Dickinson and Company's biopharma systems — revenue changed year-over-year?
- Becton, Dickinson and Company's biopharma systems — revenue decreased by 86.8% year-over-year, from $4.48B to $590.00M.
- What is the long-term trend for Becton, Dickinson and Company's biopharma systems — revenue?
- Over 4 years (2021 to 2026), Becton, Dickinson and Company's biopharma systems — revenue has grown at a -13.0% compound annual growth rate (CAGR), from $19.13B to $10.99B.
- What does biopharma systems — revenue mean?
- Total revenue generated by the BioPharma Systems business segment.